Adoptive immunotherapy of melanoma

Seth M. Pollack; Cassian Yee

doi:10.1007/9781441999146_24

Adoptive immunotherapy of melanoma

Seth M. Pollack, Cassian Yee^*

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Adoptive immunotherapy involves the ex vivo manipulation and expansion of lymphocytes to treat cancer. These lymphocytes, or effector cells, are “adoptively” transferred into the recipient and may be infused alone or as part of a regimen that includes chemotherapy, radiation therapy, exogenous cytokines and/or other biologic agents (e.g., antibodies) designed to enhance their survival and killing potential in vivo.

Original language	English (US)
Title of host publication	Innate Immune Regulation and Cancer Immunotherapy
Publisher	Springer New York
Pages	439-465
Number of pages	27
ISBN (Electronic)	9781441999146
ISBN (Print)	9781441999139
DOIs	https://doi.org/10.1007/9781441999146_24
State	Published - Jan 1 2012
Externally published	Yes

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/9781441999146_24

Cite this

@inbook{0e2fa247e7594835bcd1ee17e20ad132,

title = "Adoptive immunotherapy of melanoma",

abstract = "Adoptive immunotherapy involves the ex vivo manipulation and expansion of lymphocytes to treat cancer. These lymphocytes, or effector cells, are “adoptively” transferred into the recipient and may be infused alone or as part of a regimen that includes chemotherapy, radiation therapy, exogenous cytokines and/or other biologic agents (e.g., antibodies) designed to enhance their survival and killing potential in vivo.",

author = "Pollack, {Seth M.} and Cassian Yee",

year = "2012",

month = jan,

day = "1",

doi = "10.1007/9781441999146_24",

language = "English (US)",

isbn = "9781441999139",

pages = "439--465",

booktitle = "Innate Immune Regulation and Cancer Immunotherapy",

publisher = "Springer New York",

}

TY - CHAP

T1 - Adoptive immunotherapy of melanoma

AU - Pollack, Seth M.

AU - Yee, Cassian

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Adoptive immunotherapy involves the ex vivo manipulation and expansion of lymphocytes to treat cancer. These lymphocytes, or effector cells, are “adoptively” transferred into the recipient and may be infused alone or as part of a regimen that includes chemotherapy, radiation therapy, exogenous cytokines and/or other biologic agents (e.g., antibodies) designed to enhance their survival and killing potential in vivo.

AB - Adoptive immunotherapy involves the ex vivo manipulation and expansion of lymphocytes to treat cancer. These lymphocytes, or effector cells, are “adoptively” transferred into the recipient and may be infused alone or as part of a regimen that includes chemotherapy, radiation therapy, exogenous cytokines and/or other biologic agents (e.g., antibodies) designed to enhance their survival and killing potential in vivo.

UR - http://www.scopus.com/inward/record.url?scp=84955359937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955359937&partnerID=8YFLogxK

U2 - 10.1007/9781441999146_24

DO - 10.1007/9781441999146_24

M3 - Chapter

AN - SCOPUS:84955359937

SN - 9781441999139

SP - 439

EP - 465

BT - Innate Immune Regulation and Cancer Immunotherapy

PB - Springer New York

ER -

Adoptive immunotherapy of melanoma

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this